[Form 4] Ginkgo Bioworks Holdings, Inc. Insider Trading Activity
Ginkgo Bioworks Holdings, Inc. (DNA) reporting person Coen Steven P., identified as an officer (Chief Financial Officer), sold 5,609 shares of Class A common stock on 10/01/2025 at a reported price of $15 per share under a sales plan intended to comply with Rule 10b5-1. Following the reported disposition, the filing shows the reporting person beneficially owns 5,503 shares, held directly. The Form 4 was signed by an attorney-in-fact, Karen Tepichin, on 10/03/2025. The filing includes an explicit remark that the sale was made pursuant to a Rule 10b5-1 plan and identifies the reporting person as the company’s Chief Financial Officer.
Ginkgo Bioworks Holdings, Inc. (DNA) persona che presenta il rapporto Coen Steven P., identificato come dirigente (Chief Financial Officer), ha venduto 5.609 azioni di Class A common stock il 01/10/2025 a un prezzo riportato di $15 per azione nell'ambito di un piano di vendita volto a conformarsi alla regola 10b5-1. A seguito della disposizione riportata, nel fascicolo risulta che la persona che presenta il rapporto possiede beneficiamente 5.503 azioni, detenute direttamente. Il Form 4 è stato firmato da un procuratore (attorney-in-fact) Karen Tepichin il 03/10/2025. Il fascicolo contiene un'osservazione esplicita che la vendita è stata effettuata ai sensi di un piano Rule 10b5-1 e identifica la persona che presenta il rapporto come il Chief Financial Officer della società.
Ginkgo Bioworks Holdings, Inc. (DNA) persona informante Coen Steven P., identificado como ejecutivo (Chief Financial Officer), vendió 5,609 acciones de Class A common stock el 01/10/2025 a un precio reportado de $15 por acción, dentro de un plan de ventas destinado a cumplir con la regla 10b5-1. Tras la disposición reportada, el expediente muestra que la persona informante posee de forma beneficiosa 5,503 acciones, directamente. El Formulario 4 fue firmado por un apoderado, Karen Tepichin, el 03/10/2025. El expediente incluye una observación explícita de que la venta se realizó conforme a un plan Rule 10b5-1 e identifica a la persona informante como el Chief Financial Officer de la empresa.
Ginkgo Bioworks Holdings, Inc. (DNA) 보고자 Coen Steven P.은 임원(최고재무책임자, CFO)으로 확인되었으며, 2025년 10월 1일에 클래스 A 보통주 5,609주를 매도했고, 주당 보고가격은 $15였습니다. 이는 Rule 10b5-1을 준수하기 위한 판매 계획에 따른 매매입니다. 보고된 처분 후, 파일에는 보고자가 직접 보유한 지분이 5,503주로 표시됩니다. Form 4는 2025년 10월 3일에 대리인 Karen Tepichin이 서명했습니다. 파일에는 매도가 Rule 10b5-1 계획에 따라 이루어졌다는 명시적 문구가 포함되어 있으며 보고자를 회사의 CFO로 식별합니다.
Ginkgo Bioworks Holdings, Inc. (DNA) personne déclarant Coen Steven P., identifié comme dirigeant (Chief Financial Officer), a vendu 5 609 actions de Class A common stock le 01/10/2025 à un prix rapporté de 15 $ par action dans le cadre d'un plan de vente destiné à se conformer à la règle 10b5-1. Suite à la cession déclarée, le dossier indique que la personne déclarante détient directement 5 503 actions. Le Formulaire 4 a été signé par un mandataire, Karen Tepichin, le 03/10/2025. Le dossier comprend une remarque explicite indiquant que la vente a été effectuée conformément à un plan 10b5-1 et identifie la personne déclarante comme le Chief Financial Officer de la société.
Ginkgo Bioworks Holdings, Inc. (DNA) meldende Person Coen Steven P., identifiziert als Beauftragter (Chief Financial Officer), verkaufte am 01.10.2025 5.609 Aktien der Class A Stammaktien zu einem gemeldeten Preis von US-Dollar 15 pro Aktie im Rahmen eines Verkaufsplans, der darauf abzielt, die Rule 10b5-1 einzuhalten. Nach dem gemeldeten Abgang zeigt die Akte, dass die meldende Person direkt 5.503 Aktien besitzt. Das Formular 4 wurde am 03.10.2025 von einer Bevollmächtigten Karen Tepichin unterzeichnet. Die Einreichung enthält einen ausdrücklichen Hinweis, dass der Verkauf gemäß einem Rule 10b5-1-Plan erfolgt ist, und identifiziert die meldende Person als CFO des Unternehmens.
Ginkgo Bioworks Holdings, Inc. (DNA) الشخص المبلِغ Coen Steven P., المُعرّف كموظف (Chief Financial Officer)، باع 5,609 أسهم من Class A common stock في 01/10/2025 بسعر مُبلّغ عنه قدره $15 للسهم، بموجب خطة بيع تهدف إلى الامتثال للقاعدة 10b5-1. عقب التصرف المبلغ عنه، يُظهر الملف أن الشخص المبلِغ يمتلك فعلياً 5,503 أسهم، مملوكة مباشرة. تم توقيع النموذج 4 من قِبل وكيل/وكيلة، Karen Tepichin، في 03/10/2025. يحتوي الملف على ملاحظة صريحة بأن البيع تم وفقاً لخطة Rule 10b5-1 ويعرّف الشخص المبلِغ بأنه Chief Financial Officer للشركة.
Ginkgo Bioworks Holdings, Inc. (DNA) 报告人 Coen Steven P.，被识别为公司高管（首席财务官 CFO），在 2025/10/01 出售了 5,609 股 Class A 普通股，按每股 $15 的报告价格进行，属于旨在遵守 Rule 10b5-1 的销售计划。报告的处置后，备案显示报告人直接持有 5,503 股。Form 4 由授权代理人 Karen Tepichin 于 2025/10/03 签署。备案包含明确备注，指出此笔销售是依据 Rule 10b5-1 计划进行，并将报告人识别为公司的 首席财务官。
- Sale executed under a Rule 10b5-1 plan, indicating a pre‑arranged compliance mechanism
- Form 4 filed and signed by attorney‑in‑fact on 10/03/2025, providing timely disclosure
- Insider disposed of 5,609 shares, reducing direct beneficial ownership to 5,503 shares
Insights
TL;DR: CFO sold 5,609 shares at $15 under a Rule 10b5-1 plan; holdings now 5,503 shares.
The filing discloses a planned disposition executed on 10/01/2025 under a sales plan intended to satisfy the affirmative defense conditions of Rule 10b5-1. Using a 10b5-1 plan is a compliance practice that can limit questions about trading on material nonpublic information when the plan was adopted appropriately.
The reported remaining direct beneficial ownership is 5,503 shares after the sale of 5,609 shares, and the Form 4 was executed by an attorney-in-fact on 10/03/2025. This is a routine insider disposition disclosed under Section 16.
Ginkgo Bioworks Holdings, Inc. (DNA) persona che presenta il rapporto Coen Steven P., identificato come dirigente (Chief Financial Officer), ha venduto 5.609 azioni di Class A common stock il 01/10/2025 a un prezzo riportato di $15 per azione nell'ambito di un piano di vendita volto a conformarsi alla regola 10b5-1. A seguito della disposizione riportata, nel fascicolo risulta che la persona che presenta il rapporto possiede beneficiamente 5.503 azioni, detenute direttamente. Il Form 4 è stato firmato da un procuratore (attorney-in-fact) Karen Tepichin il 03/10/2025. Il fascicolo contiene un'osservazione esplicita che la vendita è stata effettuata ai sensi di un piano Rule 10b5-1 e identifica la persona che presenta il rapporto come il Chief Financial Officer della società.
Ginkgo Bioworks Holdings, Inc. (DNA) persona informante Coen Steven P., identificado como ejecutivo (Chief Financial Officer), vendió 5,609 acciones de Class A common stock el 01/10/2025 a un precio reportado de $15 por acción, dentro de un plan de ventas destinado a cumplir con la regla 10b5-1. Tras la disposición reportada, el expediente muestra que la persona informante posee de forma beneficiosa 5,503 acciones, directamente. El Formulario 4 fue firmado por un apoderado, Karen Tepichin, el 03/10/2025. El expediente incluye una observación explícita de que la venta se realizó conforme a un plan Rule 10b5-1 e identifica a la persona informante como el Chief Financial Officer de la empresa.
Ginkgo Bioworks Holdings, Inc. (DNA) 보고자 Coen Steven P.은 임원(최고재무책임자, CFO)으로 확인되었으며, 2025년 10월 1일에 클래스 A 보통주 5,609주를 매도했고, 주당 보고가격은 $15였습니다. 이는 Rule 10b5-1을 준수하기 위한 판매 계획에 따른 매매입니다. 보고된 처분 후, 파일에는 보고자가 직접 보유한 지분이 5,503주로 표시됩니다. Form 4는 2025년 10월 3일에 대리인 Karen Tepichin이 서명했습니다. 파일에는 매도가 Rule 10b5-1 계획에 따라 이루어졌다는 명시적 문구가 포함되어 있으며 보고자를 회사의 CFO로 식별합니다.
Ginkgo Bioworks Holdings, Inc. (DNA) personne déclarant Coen Steven P., identifié comme dirigeant (Chief Financial Officer), a vendu 5 609 actions de Class A common stock le 01/10/2025 à un prix rapporté de 15 $ par action dans le cadre d'un plan de vente destiné à se conformer à la règle 10b5-1. Suite à la cession déclarée, le dossier indique que la personne déclarante détient directement 5 503 actions. Le Formulaire 4 a été signé par un mandataire, Karen Tepichin, le 03/10/2025. Le dossier comprend une remarque explicite indiquant que la vente a été effectuée conformément à un plan 10b5-1 et identifie la personne déclarante comme le Chief Financial Officer de la société.
Ginkgo Bioworks Holdings, Inc. (DNA) meldende Person Coen Steven P., identifiziert als Beauftragter (Chief Financial Officer), verkaufte am 01.10.2025 5.609 Aktien der Class A Stammaktien zu einem gemeldeten Preis von US-Dollar 15 pro Aktie im Rahmen eines Verkaufsplans, der darauf abzielt, die Rule 10b5-1 einzuhalten. Nach dem gemeldeten Abgang zeigt die Akte, dass die meldende Person direkt 5.503 Aktien besitzt. Das Formular 4 wurde am 03.10.2025 von einer Bevollmächtigten Karen Tepichin unterzeichnet. Die Einreichung enthält einen ausdrücklichen Hinweis, dass der Verkauf gemäß einem Rule 10b5-1-Plan erfolgt ist, und identifiziert die meldende Person als CFO des Unternehmens.
FAQ
What did the Ginkgo (DNA) reporting person sell?
Was the sale part of a prearranged trading plan (10b5-1)?
How many shares does the reporting person own after the sale?
What is the reporting person’s role at Ginkgo?
When was the Form 4 signed and by whom?
